MAP2K1 and chronic myelogenous leukemia, BCR-ABL1 positive: Our findings were further reinforced by the detection of MAPK1/3 and MEK1/2 inhibition, which are all part of the MAPK pathway downstream of ABL1 and reported to be inhibited also in CML CD34+ cells [44].